Drug Ther Bull. 2012 Jul;50(7):78-80. doi: 10.1136/dtb.2012.06.0115.
▾Exenatide is a glucagon-like peptide 1 (GLP-1) agonist used in the management of people with type 2 diabetes. A twice-daily injectable formulation (▾Byetta - Eli Lilly) was licensed in 2006. ▾Bydureon (Eli Lilly) is a prolonged-release injectable formulation that allows once-weekly administration. Here we discuss the place of Bydureon in the management of type 2 diabetes mellitus.
艾塞那肽是一种用于治疗2型糖尿病患者的胰高血糖素样肽1（GLP-1）激动剂。一种每日两次注射的制剂（百泌达 - 礼来公司）于2006年获得许可。度易达（礼来公司）是一种长效注射制剂，允许每周给药一次。在此，我们讨论度易达在2型糖尿病管理中的地位。
